EA201391706A1 - Соединения (тиено[2,3-b][1,5]бензоксазепин-4-ил)пиперазин-1-ила в качестве соединений, обладающих двойной активностью обратных агонистов h1/антагонистов 5-ht - Google Patents

Соединения (тиено[2,3-b][1,5]бензоксазепин-4-ил)пиперазин-1-ила в качестве соединений, обладающих двойной активностью обратных агонистов h1/антагонистов 5-ht

Info

Publication number
EA201391706A1
EA201391706A1 EA201391706A EA201391706A EA201391706A1 EA 201391706 A1 EA201391706 A1 EA 201391706A1 EA 201391706 A EA201391706 A EA 201391706A EA 201391706 A EA201391706 A EA 201391706A EA 201391706 A1 EA201391706 A1 EA 201391706A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
benzoxazepin
ila
thieno
piperazin
Prior art date
Application number
EA201391706A
Other languages
English (en)
Other versions
EA023460B1 (ru
Inventor
Эндрю Джеймс Ледгард
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201391706A1 publication Critical patent/EA201391706A1/ru
Publication of EA023460B1 publication Critical patent/EA023460B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описаны двойной антагонист рецептора Н1/5-НТформулы:применения указанного соединения и способы получения указанного соединения.
EA201391706A 2011-07-08 2012-07-02 СОЕДИНЕНИЯ (ТИЕНО[2,3-b][1,5]БЕНЗОКСАЗЕПИН-4-ИЛ)ПИПЕРАЗИН-1-ИЛА В КАЧЕСТВЕ СОЕДИНЕНИЙ, ОБЛАДАЮЩИХ ДВОЙНОЙ АКТИВНОСТЬЮ ОБРАТНЫХ АГОНИСТОВ H1/АНТАГОНИСТОВ 5-HT EA023460B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161505685P 2011-07-08 2011-07-08
PCT/US2012/045254 WO2013009517A1 (en) 2011-07-08 2012-07-02 (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

Publications (2)

Publication Number Publication Date
EA201391706A1 true EA201391706A1 (ru) 2014-04-30
EA023460B1 EA023460B1 (ru) 2016-06-30

Family

ID=46513872

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391706A EA023460B1 (ru) 2011-07-08 2012-07-02 СОЕДИНЕНИЯ (ТИЕНО[2,3-b][1,5]БЕНЗОКСАЗЕПИН-4-ИЛ)ПИПЕРАЗИН-1-ИЛА В КАЧЕСТВЕ СОЕДИНЕНИЙ, ОБЛАДАЮЩИХ ДВОЙНОЙ АКТИВНОСТЬЮ ОБРАТНЫХ АГОНИСТОВ H1/АНТАГОНИСТОВ 5-HT

Country Status (22)

Country Link
US (1) US9481688B2 (ru)
EP (1) EP2729474B1 (ru)
JP (1) JP6050813B2 (ru)
KR (1) KR101582429B1 (ru)
CN (1) CN103703008B (ru)
AU (1) AU2012283035B2 (ru)
BR (1) BR112014000379A2 (ru)
CA (1) CA2840217C (ru)
DK (1) DK2729474T3 (ru)
EA (1) EA023460B1 (ru)
ES (1) ES2665035T3 (ru)
HR (1) HRP20180475T1 (ru)
HU (1) HUE037649T2 (ru)
IN (1) IN2014MN00144A (ru)
LT (1) LT2729474T (ru)
MX (1) MX341132B (ru)
NO (1) NO2729474T3 (ru)
PL (1) PL2729474T3 (ru)
PT (1) PT2729474T (ru)
RS (1) RS57207B1 (ru)
SI (1) SI2729474T1 (ru)
WO (1) WO2013009517A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2943498T3 (en) 2013-01-14 2017-10-23 Lilly Co Eli (THIENO [2,3-B] [1,5] BENZOXAZEPIN-4-YL) PIPERAZIN-1-YL COMPOUNDS AS H1-INVERSE AGONISTS / 5-HT2A DOUBLE EFFECTS
TW201625644A (zh) 2014-04-29 2016-07-16 美國禮來大藥廠 作為選擇性５－ＨＴＡ反向促效劑之（噻吩并［２，３－ｂ］［１，５］苯并氧氮呯－４－基）哌嗪－１－基化合物
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN108371660B (zh) * 2017-12-14 2020-03-10 五邑大学 一种四氢环戊二烯并吡咯化合物及其衍生物的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
CA2386092A1 (en) * 1999-09-29 2001-04-05 Yao-Chang Xu Piperidine derivatives
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
US7807828B2 (en) * 2005-08-11 2010-10-05 Hypnion, Inc. Olanzapine analogs and methods of use thereof
CN103214473A (zh) * 2007-03-15 2013-07-24 ARYx医疗有限公司 二苯并[b,f][1,4]氧杂氮杂*化合物
KR102184038B1 (ko) * 2008-05-27 2020-11-27 인트라-셀룰라 써래피스, 인코퍼레이티드. 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물
GB0910009D0 (en) * 2009-06-10 2009-07-22 Glaxo Group Ltd Novel compounds
AR084867A1 (es) * 2011-02-07 2013-07-10 Lilly Co Eli Compuestos de acido [(5h-pirrolo[2,1-c][1,4]benzodiazepin-11-il)piperazin-1-il]-2,2-dimetilpropanoico sustituido como antagonistas de 5-ht/agonistas inversos de actividad dual
EP2751115B1 (en) * 2011-08-30 2017-09-20 Eli Lilly and Company (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

Also Published As

Publication number Publication date
KR101582429B1 (ko) 2016-01-04
RS57207B1 (sr) 2018-07-31
JP2014518280A (ja) 2014-07-28
PT2729474T (pt) 2018-06-05
KR20140029512A (ko) 2014-03-10
AU2012283035B2 (en) 2015-07-30
CA2840217A1 (en) 2013-01-17
HUE037649T2 (hu) 2018-09-28
MX341132B (es) 2016-08-09
US20140121199A1 (en) 2014-05-01
EP2729474A1 (en) 2014-05-14
CN103703008A (zh) 2014-04-02
CA2840217C (en) 2016-03-22
EP2729474B1 (en) 2018-03-14
EA023460B1 (ru) 2016-06-30
HRP20180475T1 (hr) 2018-06-15
NO2729474T3 (ru) 2018-08-11
JP6050813B2 (ja) 2016-12-21
BR112014000379A2 (pt) 2017-01-10
CN103703008B (zh) 2015-11-25
PL2729474T3 (pl) 2018-08-31
SI2729474T1 (en) 2018-04-30
MX2014000337A (es) 2014-11-13
ES2665035T3 (es) 2018-04-24
IN2014MN00144A (ru) 2015-06-19
AU2012283035A1 (en) 2014-01-16
LT2729474T (lt) 2018-05-10
US9481688B2 (en) 2016-11-01
DK2729474T3 (en) 2018-05-22
WO2013009517A1 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
EA201490332A1 (ru) Соединения (тиено[2,3-b][1,5]бензоксазепин-4-ил)пиперазин-1-ила, обладающие двойной активностью обратных агонистов рецепторов h1/антагонистов рецепторов 5-ht
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
EA201590873A1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов
EA201391662A1 (ru) Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2
EA201491304A1 (ru) Конденсированные тетра- или пентациклические пиридофталазиноны в качестве ингибиторов parp
MX2015010679A (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H )-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3.
UY32296A (es) Nuevos compuestos
MY160665A (en) Spiropiperidine compounds as orl-1 receptor antagonists
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
RS53900B1 (en) CRYSTAL FORMS OF HYDROCHLORIDE SALTS (4A-R, 9A-S) -1- (1H-BENZOIMIDAZOL-5-CARBONYL) -2,3,4,4A, 9,9A-HEXAHIDRO-1H-INDENO [2,1-B] PIRIDIN-6-CARBONITRILA AND THEIR USE AS A HSD INHIBITOR 1
CR20140222A (es) Nuevos derivados de [1,2,3] triazolo [4,5-d] pirimidina como agonistas del receptor 2 de agonistas canabinoides
EA201491153A1 (ru) КОМПОЗИЦИИ БУПРЕНОРФИНА И АНТАГОНИСТОВ μ-ОПИОИДНЫХ РЕЦЕПТОРОВ
PE20141579A1 (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
EA201200602A1 (ru) Индазолы и пиразолопиридины в качестве антагонистов рецептора ccr1
EA201391056A1 (ru) Гетероарильные соединения в качестве лигандов 5-htрецептора
EA201391706A1 (ru) Соединения (тиено[2,3-b][1,5]бензоксазепин-4-ил)пиперазин-1-ила в качестве соединений, обладающих двойной активностью обратных агонистов h1/антагонистов 5-ht
EA201391744A1 (ru) Производные 2-амино-3-(имидазол-2-ил)-пиридин-4-она и их применение в качестве ингибиторов киназы рецептора vegf
MX2015017541A (es) Derivados de espiro [2.4] heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx.
EA201390498A1 (ru) СОЕДИНЕНИЯ 4-ЗАМЕЩЕННОГО-3-ФЕНИЛСУЛЬФАНИЛМЕТИЛБИЦИКЛО[3.1.0]ГЕКСАНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR 2/3
EA201390568A1 (ru) СОЕДИНЕНИЯ 4-ЗАМЕЩЕННОГО-3-БЕНЗИЛОКСИБИЦИКЛО[3.1.0]ГЕКСАНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGLuR 2/3
EA201390966A1 (ru) Замещенные соединения [(5h-пирроло[2,1-c][1,4]бензодиазепин-11-ил)пиперазин-1-ил]-2,2-диметилпропановой кислоты в качестве обратных агонистов h1/антагонистов 5-htдвойного действия
EA201591099A1 (ru) ТИЕНО([2,3-b][1,5]БЕНЗОКСАЗЕПИН-4-ИЛ)ПИПЕРАЗИН-1-ИЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ АГЕНТОВ С ДВОЙНОЙ АКТИВНОСТЬЮ: ОБРАТНЫХ АГОНИСТОВ H1/АНТАГОНИСТОВ 5-HT
NZ710361A (en) Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1h)-one derivatives having both β2 adrenergic receptor agonist and m3 muscarinic receptor antagonist activities
TN2013000209A1 (en) 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU